Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022461 | 0.88 | CCNB2 (0.53) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3744999 | 0.85 | ALDH1A1 (0.49) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL865350 | 0.83 | MAOA (0.58) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL13956364 | 0.83 | ERN1 (0.52) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3409441 | 0.81 | PTGER4 (0.67) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3409444 | 0.81 | PTGER4 (0.67) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL4754158 | 0.81 | L3MBTL1 (0.51) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL4427861 | 0.81 | CCR5 (0.50) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL8409065 | 0.81 | SLC6A4 (0.50) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL3035265 | 0.81 | MAPT (0.50) | CCNB2CDK1CDK4CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829588-B2 | Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-09 | — | — | US | disclosed |
| CN-101679216-A | Novel 3-phenylpropionic acid derivatives as activators for receptors of the PPAR type, process for their preparation and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV | 2010-03-24 | — | — | CN | disclosed |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-18 | — | — | US | disclosed |
| CN-101573033-A | Heterocyclyl-substituted anti-hypercholesterolemic compounds | MERCK & CO INC (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2086324-A2 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008057336-A2 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057336-A2 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
| CN-101022810-A | Novel biaromatic compounds which activate peroxisome proliferator activated receptor-like receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2007-08-22 | — | — | CN | disclosed |
| EP-1781274-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| EP-1694669-B1 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2007-04-11 | — | — | EP | disclosed |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1694669-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006018325-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005058844-A2 | NOVEL COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069347-A1 | HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | LDLR, PCSK9, CYP46A1 | CCNB2 1447/4885CDK1 2092/4885CDK4 3744/4885 |
| US-20070054907-A1 | Peroxisome Proliferator-Activated Receptor (PPAR) receptor modulators such as Ethyl(4-{4-[5-(4-tert-butylphenyl)-4-methyl-4H-[1,2,4]-triazol-3-ylsulfanyl]-2-heptyloxybenzylamino}phenyl)acetate, used in dermatology, cardiovascular diseases, immunology and/or diseases linked to lipid metabolism | PPARG, PPARA, PPARD | CCNB2 4567/4885CDK1 4412/4885CDK4 1585/4885 |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | CCNB2 4045/4885CDK1 4237/4885CDK4 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.